# Phase III Clinical Study of Azvudine in Hiv-infected Treatment Naive Patients

> **NCT04303598** · PHASE3 · UNKNOWN · sponsor: **Henan Genuine Biotech Co., Ltd.** · enrollment: 720 (estimated)

## Conditions studied

- HIV-infection/Aids

## Interventions

- **DRUG:** FNC
- **DRUG:** 3TC
- **DRUG:** TDF
- **DRUG:** EFV
- **DRUG:** FNC placebo
- **DRUG:** 3TC placebo

## Key facts

- **NCT ID:** NCT04303598
- **Lead sponsor:** Henan Genuine Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04-01
- **Primary completion:** 2022-05-01
- **Final completion:** 2022-08-01
- **Target enrollment:** 720 (ESTIMATED)
- **Last updated:** 2020-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04303598

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04303598, "Phase III Clinical Study of Azvudine in Hiv-infected Treatment Naive Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04303598. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*